Technology

Cardiovascular disease (CVD) is the most common cause of death worldwide. Despite commitments to reduce cardiovascular mortality by 25% until 2025, most countries are not on course to meet their targets by this date.*  

Hypercholesterolemia, a high blood cholesterol concentration, is the most important risk factor for CVD and cholesterol-lowering therapy is widely used to reduce CVD incidence. However, people respond differently to cholesterol-lowering drugs and most patients do not achieve their blood cholesterol target levels, leaving them at high risk for CVD. Currently, doctors do not know how a patient will respond to a given treatment and they determine the optimal strategy in an inefficient trial-and-error approach.  

Our unique solution provides novel insight into why individual patients respond differently to cholesterol-lowering drugs. This allows us to establish novel personalized medicine applications for hypercholesterolemia, easing the selection of the optimal treatment strategy for a patient. With this, more patients will achieve their treatment goals faster, reducing CVD risk and saving lives. 

*https://www.who.int/publications/i/item/ncd-progress-monitor-2020